Considerable research over the past decade has thrown up two novel antibiotic preparations which are effective in 'difficult' Gram positive infections. Their imminent arrival is welcomed at a time when the emergence of resistance to last line drugs is rapidly spreading. Their careful use is, however, crucial if long-term value is to be preserved.